Patents by Inventor Dora Kovacs

Dora Kovacs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions relating to modulating amyloid precursor protein cleavage
    Publication number: 20050170437
    Abstract: The invention relates in part assays for identifying and testing compounds that modulate cleavage of amyloid precursor protein (APP). In addition, the invention relates to novel cleavage products of APP. The invention additionally relates to methods and assays for identifying compounds that inhibit acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity. The methods and products of the invention are useful for identifying compounds to prevent and/or treat APP-cleavage associated disorders (e.g. Alzheimer's disease) and are also useful for identifying compounds to prevent and/or treat ACAT-associated disorders.
    Type: Application
    Filed: November 8, 2004
    Publication date: August 4, 2005
    Applicant: The General Hospital Corporation
    Inventors: Luigi Puglielli, Henri Huttunen, Suzanne Guenette, Rudolph Tanzi, Dora Kovacs
  • Methods for treating ACAT-related diseases
    Publication number: 20050118226
    Abstract: The invention relates to methods for administering inhibitors of acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity, and for treating Alzheimer's disease, atherosclerosis, and other ACAT-related diseases. The invention also relates to sustained release delivery systems.
    Type: Application
    Filed: November 8, 2004
    Publication date: June 2, 2005
    Inventors: Dora Kovacs, Luigi Puglielli, Rudolph Tanzi, Matthew Frosch
  • &agr;-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
    Patent number: 6472140
    Abstract: The disclosed invention relates to the finding that the A2M-2 deletion mutation, which is a predisposing factor for Alzheimer's Disease, leads to the production of altered &agr;2M RNA transcripts and proteins. Based on this finding, the invention provides for new therapeutic agents for AD, including molecules having A&bgr; and low density lipoprotein receptor-related protein (LRP) binding domains, peptides, nucleic acid molecules, antisense oligonucleotides, and viral vectors for gene therapy. In addition, the invention relates to pharmaceutical compositions containing these therapeutic agents, methods of using these therapeutic agents to combat Alzheimer's Disease, and methods of screening for therapeutic agents that can combat Alzheimer's Disease.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: October 29, 2002
    Assignee: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Dora Kovacs, Aleister J. Saunders
  • Alpha-2-macroglobulin therapies and drug screening methods for Alzheimer's disease
    Publication number: 20020114792
    Abstract: The disclosed invention relates to the finding that the A2M-2 deletion mutation, which is a predisposing factor for Alzheimer's Disease, leads to the production of altered &agr;2M RNA transcripts and proteins. Based on this finding, the invention provides for new therapeutic agents for AD, including molecules having A&bgr; and low density lipoprotein receptor-related protein (LRP) binding domains, peptides, nucleic acid molecules, antisense oligonucleotides, and viral vectors for gene therapy. In addition, the invention relates to pharmaceutical compositions containing these therapeutic agents, methods of using these therapeutic agents to combat Alzheimer's Disease, and methods of screening for therapeutic agents that can combat Alzheimer's Disease.
    Type: Application
    Filed: January 23, 2002
    Publication date: August 22, 2002
    Applicant: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Dora Kovacs, Aleister J. Saunders